Estimated drop
16D : 14H : 21M : 32S
Ozempic prices are dropping by up to 65%
Generic semaglutide contains the same active ingredient as Ozempic and Wegovy. While we can't guarantee specific pricing, increased competition typically drives costs down across both brand-name and generic medications, and similar launches have seen prices drop by up to 65%.
We expect to make these available to CanAmerica Plus members in the coming weeks.
Sign up below to get notified when prices drop.
FAQ
Generic medications are essentially copies of brand-name medications. They are authorized for sale having the exact same active pharmaceutical ingredients and therapeutic effect as the original brand.
In Canada, the government and generic manufacturers have a pricing framework in place that lowers the price of generics as more of them enter the market. Learn more about the generic pricing framework here.
| Number of generics | Est. generic price (vs. brand)* |
|---|---|
| 1 generic available | $240 per pen (~75% of brand price) |
| 2 generics available | $160 per pen (~50% of brand price) |
| 3 or more generics available | $112 per pen (~35% of brand price) |
*Based on the current brand price of $320 per pen.
Brand-name prices are also expected to drop as competition increases.
Yes. Generic medications are strictly regulated to ensure they are just as safe, effective, and high-quality as the original brand-name drugs. To be authorized for sale, generic medications must contain the same active ingredient, be the same strength, dosage, and form, work the same way in the body, and meet the same safety, quality, and manufacturing standards.
The first generic semaglutide approved in Canada is manufactured by Dr. Reddy's Laboratories. Market approval follows a rigorous review process to ensure generic medications contain the same active ingredient and meet the same safety, quality, and manufacturing standards as the original brand-name drug.
The first generic semaglutide was approved by Health Canada on April 28, 2026 (manufactured by Dr. Reddy's Laboratories). Eight additional generic submissions are currently under review. Prices will likely fall in stages as more generic manufacturers enter the market. It may also take some time for these companies to scale up production, so availability could be limited at first or sporadic throughout the year depending on demand and production capacity. Coverage under provincial drug plans will vary by province and is not yet confirmed.
Because only semaglutide is going off-patent, lower prices are expected for semaglutide medications, but not necessarily others.